CLDN6 and sarcoma: Also, we observed that CLDN6 expression was associated with immune stimulators (Supplementary Figure 1) and immune inhibitors (Supplementary Figure 2) in the majority of malignant tumors except for KIRC, kidney renal papillary cell carcinoma (KIRP), LGG, LIHC, PCPG, prostate adenocarcinoma (PRAD), READ, sarcoma (SARC), and skin cutaneous melanoma (SKCM).